Dj. Katzmann et al., TRANSCRIPTIONAL CONTROL OF THE YEAST PDR5 GENE BY THE PDR3 GENE-PRODUCT, Molecular and cellular biology, 14(7), 1994, pp. 4653-4661
Saccharomyces cerevisiae cells possess the ability to simultaneously a
cquire resistance to an array of drugs with different cytotoxic activi
ties. The genes involved in this acquisition are referred to as pleiot
ropic drug resistant (PDR) genes. Several semidominant, drug resistanc
e-encoding PDR mutations have been found that map near the centromere
on chromosome II, including PDR3-1 and PDR4-1. DNA sequencing of chrom
osome II identified a potential open reading frame, designated YBL03-2
3, that has the potential to encode a protein with strong sequence sim
ilarity to the product of the PDR1 gene, a zinc finger-containing tran
scription factor. Here,ve show that YBL03-23 is allelic with PDR3. The
presence of a functional copy of either PDR1 or PDR3 is essential for
drug resistance and expression of a putative membrane transporter-enc
oding gene, PDR5. Deletion mapping of the PDR5 promoter identified a r
egion from -360 to -112 that is essential for expression of this gene.
DNase I footprinting analysis using bacterially expressed Pdr3p showe
d specific recognition by this protein of at least one site in the -36
0/-112 interval in the PDR5 promoter. A high-copy-number plasmid carry
ing the PDR3 gene elevated resistance to both oligomycin and cyclohexi
mide. Increasing the number of PDR3 gene copies in a Delta pdr5 strain
increased oligomycin resistance but was not able to correct the cyclo
heximide hypersensitivity that results from loss of PDR5. These data a
re consistent with the notion that PDR3 acts to increase cycloheximide
resistance by elevating the level of PDR5 transcription, while PDR3-m
ediated oligomycin resistance acts through some other target gene.